Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a globally renowned leader in scientific solutions, providing instruments, reagents, software, and services critical to the life science and healthcare sectors. The company is a prominent player in synthetic biology, offering an extensive portfolio of products that includes Cas9 nucleases and gene editing mRNA pairs essential for research and development. Thermo Fisher’s major strength lies in its diverse product lines and strong global footprint, enabling it to support complex genomic analysis and high-throughput research. It actively pursues both organic and inorganic growth strategies, exemplified by its partnership with institutions like the National Cancer Institute (NCI) to expedite research into novel treatments for complex diseases. By integrating advanced molecular tools and technologies, Thermo Fisher Scientific provides the necessary infrastructure to accelerate drug discovery and diagnostics development, cementing its position as a key global enabler in the synthetic biology market.
Latest Market Research Report on Synthetic Biology Download PDF Brochure Now
Merck KGaA
Merck KGaA is a leading German pharmaceutical and chemical manufacturer recognized for its significant presence in the global synthetic biology market. The company offers a comprehensive selection of products, most notably CRISPR and Gene editing tools, which are fundamental to modern genetic engineering and biotechnological research. Merck is committed to meeting the growing demand for biopharmaceuticals by investing heavily in biomanufacturing technologies designed to boost the capacity and productivity of biological production processes. The corporation also utilizes strategic inorganic growth approaches, such as the acquisition of Mirus Bio in 2024, which specializes in products aiding in the manufacture of viral vectors for cell and gene therapies. This strategic focus on tools, technology, and manufacturing support establishes Merck KGaA as a vital partner for researchers and industry stakeholders driving advancements in synthetic biology.
Ginkgo Bioworks
Ginkgo Bioworks, established in 2008 as a spinout from the Massachusetts Institute of Technology, is a synthetic biology company specializing in designing and engineering organisms for diverse commercial applications. The company operates its proprietary ‘Foundry’ platform, which is engineered to enable high-throughput design and construction of biological systems. Ginkgo Bioworks leverages its expertise to create engineered organisms capable of producing a wide range of high-value products, including flavors, fragrances, industrial enzymes, nutritional ingredients, and pharmaceuticals. As one of the largest global suppliers of synthetic DNA, Ginkgo Bioworks partners extensively with leading pharmaceutical and biotechnology firms. This collaborative approach allows them to integrate their powerful synthetic biology technologies into industrial production pipelines, driving the development of innovative and sustainable bio-based products worldwide.
Twist Bioscience
Twist Bioscience is an innovative company focused on synthesizing DNA through its proprietary silicon-based platform. Founded in 2013, the company commercializes next-generation platforms for highly accurate and rapid DNA synthesis. The core technology uses a high-throughput semiconductor-based process that miniaturizes the chemistry required for DNA synthesis, allowing millions of oligonucleotides to be synthesized simultaneously in nano-wells on a silicon wafer. This method drastically reduces the cost and time associated with generating large volumes of synthetic DNA and genes. Twist Bioscience’s high-quality, DNA-based tools are enabling researchers across multiple scientific disciplines to accelerate groundbreaking discoveries in areas like drug development, diagnostics, and sustainable industrial bioproducts, positioning the company as a key infrastructure provider in the modern synthetic biology ecosystem.
Agilent Technologies Inc.
Agilent Technologies Inc. is a global leader in analytical instrumentation and laboratory systems, deeply invested in advancing synthetic biology through its technology platforms. Originating as a spin-off from Hewlett-Packard, Agilent provides essential instruments, software, and consumables for life sciences, diagnostics, and chemical analysis. The company’s synthetic biology contributions focus on next-generation sequencing workflow tools, DNA synthesis tools, and genome editing technologies. Agilent’s solutions are designed to enhance high throughput and reproducibility, particularly in complex research areas like genomics and single-cell analysis. A prime example is their use of microfluidic chips in products like the Bioanalyzer Protein kits, which streamline assays and provide high-quality sample analysis, reinforcing Agilent’s role in empowering researchers to achieve rapid and accurate scientific breakthroughs.
GenScript
GenScript is a global biotechnology company founded in 2002, specializing in providing comprehensive products and services for life science research and development. The company’s core business segments include life science services, biologics development, industrial synthetic biology products, and cell therapy solutions, with operations spanning the US, China, and Europe. In synthetic biology, GenScript is a major provider of custom services such as high-quality gene synthesis, protein expression, DNA sequencing, and protein engineering. They offer highly customizable, tailor-made solutions that support researchers through every phase of the DNA-RNA-Protein workflow, including the design and construction of synthetic genes and pathways. GenScript’s commitment to providing one-stop solutions and its large market presence solidify its standing as a leading molecular services partner in the synthetic biology industry.
Amyris, Inc.
Amyris, Inc. is a US-based synthetic biotechnology company established in 2003, focused on sustainable ingredient manufacturing using its proprietary technology platform. The company employs synthetic biology to develop and commercialize specialty chemicals, utilizing sugarcane fermentation to convert plant sugars into high-value bioidentical molecules. Amyris developed the Hyper-integration for rapid yeast strain engineering (Hi-Ryse) platform, which enables efficient design, engineering, optimization, and scalable fermentation of synthetic biology-developed organisms. Their bio-based ingredients are integrated into various consumer and industrial products, including anti-wrinkle skincare, zero-calorie sweeteners, fine fragrances, and polymers. Amyris’s work demonstrates the successful application of synthetic biology principles toward sustainable, commercial-scale production, driving innovation in the global bioeconomy.
Codexis, Inc.
Codexis, Inc. is a biotechnology company founded in 2002 that discovers, develops, and commercializes high-performance enzymes and proteins for a variety of sectors, including pharmaceuticals, fine chemicals, and biotherapeutics. The company’s primary synthetic biology asset is the Code Evolver platform, which leverages advanced gene variant libraries to create biocatalysts with new or optimized functions. This technology enables the rapid engineering of custom enzymes tailored for specific industrial applications. By providing these specialized tools, Codexis helps customers streamline chemical and pharmaceutical manufacturing processes, enhance product quality, and promote sustainability. Codexis is thus positioned as a critical provider of engineered protein solutions derived from synthetic biology principles.
Precigen (PGEN)
Precigen is a biotechnology company utilizing synthetic biology to develop innovative medicines and therapies across several disease areas. The company focuses on the application of advanced genetic engineering to create precision health solutions. Although detailed platform information may be proprietary, Precigen is recognized as a prominent player leveraging synthetic biology to engineer biological systems, particularly for therapeutic applications within the biotechnology sector. Their efforts are directed toward creating novel treatments that address complex diseases, showcasing the transformative potential of synthetic biology beyond research tools and into direct clinical impact. Precigen’s strategy involves continuously developing and refining its genetically engineered programs to drive advancements in next-generation precision medicine.
Novozymes A/S
Novozymes A/S, founded in 2000, is a Denmark-based global biotechnology company and the world’s largest producer of industrial enzymes, maintaining a substantial global market share. Novozymes applies synthetic biology principles to develop and manufacture a broad portfolio of industrial enzymes, microorganisms, and biopharmaceutical ingredients. These products are vital to various industries, including household detergents, bioenergy, food and beverage, and agriculture. By continuously innovating in enzyme technology and leveraging strategic acquisitions, Novozymes provides crucial biological solutions that increase efficiency, reduce resource consumption, and enhance sustainability for their industrial partners globally, reinforcing its role as a foundational company in industrial synthetic biology.
Latest Market Research Report on Synthetic Biology Download PDF Brochure Now